This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.
KISQALI® (ribociclib) resources
Indications:1
Advanced breast cancer (aBC)
KISQALI is indicated for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor (AI) or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy (ET).
In pre/perimenopausal women, the ET should be combined with a a luteinising hormone-releasing hormone (LHRH) agonist
Early breast cancer (eBC)
KISQALI in combination with an AI, is indicated for the adjuvant treatment of patients with HR+/HER2– eBC at high risk of recurrence (see section 5.1 of the SmPC for eligibility criteria)
In pre/perimenopausal women, or in men, the AI should be combined with an LHRH agonist
KISQALI is not recommended to be used in combination with tamoxifen.
Support for KISQALI prescribers
Explore our growing library of resources designed to support healthcare professionals prescribing KISQALI in both aBC and eBC. You can preview and download any of these tools to use in your own time.
To receive more information or printed copies of any materials, please contact a Novartis representative.
Resources for HCPs
Video resources for HCPs
Prof. Peter Fasching patient case study
Dr Caroline Michie patient case study
Dr Mark Verrill patient case study
Dr Mark Tuthill patient case study
Dr Alastair Thomson patient case study
Bleddyn Edwards patient case study
Dr Vivek Misra assessment of frailty and CDK4/6i eligibility
Dr Vivek Misra treatment goals for HR+/HER2– aBC
Prof. Peter Fasching treatment goals in aBC
Resources for patients
Resources for HCPs
Video resources for HCPs
Prof. Peter Fasching 4-year outcomes from the NATALEE trial
Prof. Stephen Johnston risk of recurrence in HR+/HER2– eBC
Tej Quine virtually assessed pathway (VAP) clinic
Resources for patients
The KISQALI & Kardia package deal gives your patients access to technology to supplement cardiology clinical practice.
The KISQALI & Kardia package deal is organised and funded by Novartis Pharmaceuticals Ltd.
aBC, advanced breast cancer; AI, aromatase inhibitor; CDK4/6i, cyclin dependent kinase 4/6 inhibitor; eBC, early breast cancer; ET, endocrine therapy; HER2–, human epidermal growth factor receptor 2 negative; HR+, hormone receptor positive; LHRH, luteinising hormone-releasing hormone; SmPC, summary of product characteristics.
Reference
KISQALI® (ribociclib) Summary of Product Characteristics.
UK | October 2025 | 442310
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
Welcome to Pro.Novartis.com
The Novartis portal for UK healthcare professionals (HCPs) and other relevant decision makers* is where you can find promotional information about Novartis products, therapy area materials and professional resources.
*Other relevant decision makers particularly includes those with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply or use of any medicine but who are not health professionals.
This website is designed to be viewed on desktop.
Welcome to Pro.Novartis.com
The Novartis portal for UK healthcare professionals (HCPs) and other relevant decision makers* is where you can find promotional information about Novartis products, therapy area materials and professional resources.
*Other relevant decision makers particularly includes those with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply or use of any medicine but who are not health professionals.
This website is designed to be viewed on desktop.